Providers/Grant Support
This program is supported by grants from AbbVie Inc. and Ironwood Pharmaceuticals, Inc, and Salix Pharmaceuticals.
Credits Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of primary care clinicians and other healthcare professionals who care for patients with irritable bowel syndrome (IBS).
Program Overview
IBS is a common functional gastrointestinal disorder with a significant negative impact on patient quality of life that is commonly managed in primary care. Despite its high prevalence, IBS remains underdiagnosed and undertreated, with affected individuals often experiencing diagnostic delays, inadequate symptom control, and persistent impairments in daily functioning. The absence of reliable biomarkers, heterogeneous pathophysiology, and ongoing reliance on exclusionary diagnostic approaches contribute to shortcomings in care.
Join our expert faculty to review symptom-based diagnostic criteria, appropriate use of testing, current evidence-based treatment options, and practical strategies for individualized care. The program will also address communication approaches to promote shared decision-making and optimize long-term outcomes for patients with IBS.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Apply Rome IV criteria to achieve earlier diagnosis of IBS
- Create a treatment plan that is consistent with current evidence-based guidelines for patients with IBS
- Utilize evidence-based communication strategies and shared decision-making to identify patient needs and guide the treatment of IBS
Faculty
Darren M. Brenner, MD
Professor of Medicine and Surgery
Department of Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Darren M. Brenner, MD
Advisor, Speaker, Consultant: AbbVie, Aradelyx, Ironwood, Salix
Board of Directors: International Foundations for GI Disorders
Consultant: Alnylam, Bayer, BioAmerica, CinPhloro, Dr. Reddy, Gemelli, Laborie, Vibrant
Non-vested Stock Options: Owlstone, SideBy Care
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2026 through April 8, 2027, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].